MERS (Middle East Respiratory Syndrome)
5
0
0
2
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
6 treatments under study, led by Bvrsgamvac
Research Leaders
16 sponsors active, led by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
20.0%
1 terminated out of 5 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS
Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)
Study of Safety and Immunogenicity of BVRS-GamVac-Combi
Study of Safety and Immunogenicity of BVRS-GamVac
Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
Research Network
Common Treatments
- Bvrsgamvac1
- Mvamerssdf1 Low Dose1
- Vaccine Candidate Mvamerss1
- Bvrsgamvaccombi1
- Mvamerssdf1 High Dose1
Active Sponsors
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation2
- Bernhard Nocht Institute for Tropical Medicine1
- IDT Biologika Dessau.Rossau1
- Ludwig-Maximilians - University of Munich1
- University of Oxford1
Top Investigators
Universitätsklinikum Hamburg-Eppendorf
ECO-Safety
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
Related Conditions
- Mers2